Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe N. Amaria, Amir A. Jazaeri, Cara Haymaker et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 54
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosisAnne Knisely, Amir A. Jazaeri, Emily Hinchcliff et al.|Med|2024Cited by 10
Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.Anne Knisely, Amir A. Jazaeri, Hind Rafei et al.|Journal of Clinical Oncology|2024Cited by 9
Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancerAnne Knisely, Amir A. Jazaeri, Emily Hinchcliff et al.|iScience|2024Cited by 5
Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors.Rodabe N. Amaria, Amir A. Jazaeri, David Vining et al.|Journal of Clinical Oncology|2022Cited by 3